AUC

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 9, 2023
ACRV, Neoplasm, Science, Patient, Research, AACR, IND, AUC, Ovarian cancer, Biomarker, Endometrial cancer, LDG, Conference, WEE1, Development, PKMYT1, Clinical trial, Medicine, PDX, Carcinoma, Sensitivity, Therapy, Cancer, AP3, Pharmaceutical industry, Medical imaging, Cryptocurrency

WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

Key Points: 
  • WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.
  • Net loss for the quarter ended September 30, 2023 was $14.5 million compared to a net loss of $9.2 million for the same period in 2022.
  • Research and development expenses were $10.3 million for the quarter ended September 30, 2023 compared to $7.9 million for the same period in 2022.
  • General and administrative expenses were $5.9 million for the quarter ended September 30, 2023 compared to $1.6 million for the same period in 2022.

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Bispecific monoclonal antibody, Patient, FDA, PD-L1, Trial of the century, IND, Therapy, Paclitaxel, G&A, AUC, PD-1, Doctor of Philosophy, Entrepreneurship, Stage 2, Development, CRC, Key Stage 1, Research and development, DLL4, Safety, Management, Fine chemical, Nursing, Pharmaceutical industry, Cryptocurrency, Research, Compass, MD, BTC

Transition to take place on January 9th 2024

Key Points: 
  • Transition to take place on January 9th 2024
    Ended the third quarter with $164 million in cash and marketable securities, providing cash runway for the company into 2026
    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date, 2023 financial results.
  • During the first nine months of 2023, the Company used $28 million of cash to fund operations.
  • R&D expenses were $8.8 million for the quarter ended September 30, 2023, as compared to $9.8 million for the same period in 2022, a decrease of approximately $1.0 million or 10%.
  • G&A expenses were $3.1 million for the quarter ended September 30, 2023, as compared to $2.8 million for the same period in 2022, an increase of $0.3 million or 10%.

PreCheck Receives Contract for Employment and Background Screening Services from Vizient

Retrieved on: 
Thursday, November 9, 2023
Senior, TSA PreCheck, Safety, Workforce, AUC, Nursing, Vizient, Inc., Health care

HOLTSVILLE, N.Y., Nov. 9, 2023 /PRNewswire-PRWeb/ -- PreCheck, a healthcare exclusive employment and background screening firm, announced today it has been awarded an agreement from Vizient, the largest provider-driven healthcare performance improvement company in the nation, to offer services to Vizient provider customers at negotiated pricing. The contract went into effect Oct.1.

Key Points: 
  • Healthcare background screening firm PreCheck has been awarded a contract from Vizient to provide negotiated customer pricing.
  • HOLTSVILLE, N.Y., Nov. 9, 2023 /PRNewswire-PRWeb/ -- PreCheck, a healthcare exclusive employment and background screening firm, announced today it has been awarded an agreement from Vizient, the largest provider-driven healthcare performance improvement company in the nation, to offer services to Vizient provider customers at negotiated pricing.
  • PreCheck's expertise in background screening can provide healthcare organizations with the tools they need to hire and retain the best talent while maintaining a commitment to patient safety and care quality.
  • The contract will enable Vizient customer healthcare organizations to access a comprehensive range of background screening and workforce solutions at negotiated pricing that support their mission to provide high-quality, cost-effective patient care.

DASYNOC™ Uptake into the Blood Remains Consistent When Taken with Omeprazole, Whereas SPRYCEL® Uptake is Significantly More Impaired than Previously Understood

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Pharmaceutical, Health, Oncology, PH, FDA, AUC, PPI, Omeprazole, Physician, CML, HIV disease progression rates, Dasatinib, Risk, TKI, Blood, Patient, Death, Solubility, Pharmaceutical industry, Cmax

Xspray has demonstrated that in the DASYNOC CO-PPI Study, DASYNOC’s uptake into blood was not affected 10 hours after taking omeprazole (107 % of intended AUC0-24h and 86% of intended Cmax).

Key Points: 
  • Xspray has demonstrated that in the DASYNOC CO-PPI Study, DASYNOC’s uptake into blood was not affected 10 hours after taking omeprazole (107 % of intended AUC0-24h and 86% of intended Cmax).
  • However, in the SPRYCEL CO-PPI Study, the uptake of SPRYCEL was significantly reduced 10 hours after taking omeprazole (only 12% of the intended AUC0-24h and 4% of the intended Cmax).
  • “We recently published that CML patients, concomitantly treated with TKIs and PPIs, are at a statistically significant 3.5-fold increased risk of death.
  • SPRYCEL was approved in 2006 by the FDA and is the market leading branded product that revolutionized the treatment of CML.

Mytonomy Recognized by Deloitte as One of the 500 Fastest-Growing Tech Companies in North America

Retrieved on: 
Wednesday, November 8, 2023
Cloud, Fintech, Patient, Education, Health care, AUC, Creativity, Deloitte Technology Fast 500, Health education, Perseverance, Growth, LLP, Hospital, Telecommunications, Device, Automation, Communication, Pharmaceutical industry, Nursing, Pharma

BETHESDA, Md., Nov. 8, 2023 /PRNewswire-PRWeb/ -- Mytonomy, a leader in healthcare cloud solutions for video-based patient education and engagement, announced today it ranked #402 on the Deloitte Technology Fast 500™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.

Key Points: 
  • - Anjali Kataria, CEO & Co-founder
    Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2019 to 2022.
  • Mytonomy Cloud for Healthcare is the enterprise platform enabling healthcare providers to engage effectively with their patients digitally.
  • Mytonomy supports every major medical condition across all care settings, facilitating more than 300 patient journeys out of the box.
  • "Each year we look forward to reviewing the progress and innovations of our Technology Fast 500 winners.

Robinhood Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023
Crypto, Adjustment, Active users, AUC, ARPU, SBC, MAU, Cryptocurrency, EBITDA, IRA, Fraud, Robinhood Markets, GAAP, Gold, Acquisition, Entrepreneurship, Growth, EPS, ETF, Net, Investment, Movement, Securities lending, EU, Bank, Financial services, Automotive industry, Video game, Beauty salon, Q3

MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced financial results for the third quarter of 2023, which ended September 30, 2023.

Key Points: 
  • MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced financial results for the third quarter of 2023, which ended September 30, 2023.
  • Q3 2023 EPS of -$0.09 included -$0.11 per share impact from a regulatory accrual of $104 million.
  • Robinhood will host a conference call to discuss its results at 2 p.m. PT / 5 p.m.
  • Based on our Q3 2023 results, our expense outlook for 2023 has changed from our prior outlook at Q2 2023 earnings (August 2, 2023).

Mary Kay Ash Foundation℠ Celebrates Five Years Shaping the Future of Cancer Research in Partnership With UT Southwestern Medical Center

Retrieved on: 
Tuesday, November 7, 2023
Cosmetics, Retail, Oncology, Women, Philanthropy, Hospitals, Catalog, Fund Raising, Foundation, Science, Other Philanthropy, Other Science, Consumer, Research, Health, Fashion, Knowledge, University of Texas Southwestern Medical Center, Human, São Paulo, Publication, AUC, Front Row, Multimedia, Mentorship, Partnership, Cancer, Cell biology, University, Woman, Class, Harold, Shanghai Jiao Tong University, Pharmaceutical industry, Nursing, Geriatrics

Hosted at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, the fellowship is a two-year postdoctoral program sponsored by the Mary Kay Ash Foundation.

Key Points: 
  • Hosted at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, the fellowship is a two-year postdoctoral program sponsored by the Mary Kay Ash Foundation.
  • View the full release here: https://www.businesswire.com/news/home/20231107256704/en/
    International Postdoctoral Scholars in Cancer Research, Class of 2023.
  • “For more than two decades, the Mary Kay Ash Foundation and UT Southwestern Medical Center have partnered in a continued commitment to find cures for cancers affecting women,” said Michael Lunceford, President, Mary Kay Ash Foundation Board of Directors.
  • “We appreciate Mary Kay Ash Foundation’s continued investment in UT Southwestern Medical Center and the future of cancer research.

New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Neurology, Mental Health, Other Science, Research, Science, Clinical Trials, Physiology, Receiver, Plasma, AUC, Ageing, Biomarker, NP, Pathology, Disease, PET, University, APOE, Brain, Classification, Diagnosis, Patient, CI, Medical imaging, Neuroscience, Medicine

C2N analyzed the biomarkers using its high-resolution mass spectrometry (MS) analytical platform as part of this study.

Key Points: 
  • C2N analyzed the biomarkers using its high-resolution mass spectrometry (MS) analytical platform as part of this study.
  • All participants underwent amyloid PET scans, and 340 (32%) participants had positive PET scan findings (defined as Centiloid scale > 20).
  • Among the individual biomarkers evaluated, plasma p-tau217/np-tau217 had highest accuracy followed next by Aβ42/Aβ40 and last by p-tau181/np-tau181 for identifying amyloid PET status.
  • “The blood biomarkers with the highest performance in the study are the biomarkers highlighted in the Precivity blood tests, demonstrating the application of these biomarkers for important research purposes.

Genialis Presents Data at SITC 2023 on RNA-Based Biomarkers to Predict Immunotherapy Response

Retrieved on: 
Friday, November 3, 2023
Technology, Genetics, Clinical Trials, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Oncology, Society for Immunotherapy of Cancer, RNA-Seq, Exact sciences, AUC, Biomarker, Therapy, RNA, Colorectal cancer, Data, PCR, MSI, SITC, Cancer systems biology, San Diego Convention Center, Immunotherapy, Disease, NGS, Microsatellite instability, Biology, Annual general meeting, Biomarker discovery, Gene, Algorithm, Society, Patient, Abstract, DNA, Vaccine, Genial

Genialis , the RNA-biomarker company, today announced new data detailing how RNA sequencing data can help elucidate tumor biologies that may be amenable to immunotherapies and targeted agents.

Key Points: 
  • Genialis , the RNA-biomarker company, today announced new data detailing how RNA sequencing data can help elucidate tumor biologies that may be amenable to immunotherapies and targeted agents.
  • The information was presented in two posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting .
  • “RNA biomarkers provide more comprehensive and dynamic insights into cellular states and regulatory processes compared with DNA or protein biomarkers.
  • For more information on ResponderID or to make an appointment with Genialis to learn more, please visit www.genialis.com

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Medical Devices, Health, Genetics, Oncology, Genetic testing, Patient, Journal of the American Society of Nephrology, Kidney disease, Columbia University Irving Medical Center, Hematuria, Therapy, Medicare, Physician, AUC, Diabetes, NTRA, Journal, Society, Chronic kidney disease, Disease, Division, Medicine, Hypertension, Histology, Biopsy, Nephrology, CKD, Diagnosis, DNA, Pharmaceutical industry, Medical imaging, Dietary supplement

Genetic testing can address many of these limitations by identifying the underlying origin of disease, enabling physicians to properly diagnose and stratify CKD patients.

Key Points: 
  • Genetic testing can address many of these limitations by identifying the underlying origin of disease, enabling physicians to properly diagnose and stratify CKD patients.
  • In the RenaCARE study, 20.8% of CKD patients had a positive genetic finding.
  • Of those, 48.8% of patients received a new or reclassified diagnosis and 34% received information on disease subtype.
  • In the study, 35.5% of patients with positive results received a diagnosis that could make them eligible for available therapeutics.